Compare Exelon Corporation Common Stock (EXC) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelon Corporation Common Stock vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Exelon Corporation Common Stock trades at $41.74 (market cap $42.99B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Exelon Corporation Common Stock pays the higher dividend (4.03%). Which is the better fit depends on your goals.
| EXC | TAK | |
|---|---|---|
Market Cap | $42.99B | $58.74B |
Volume | 7,570,408 | 3,110,994 |
Sector | Utilities | Health |
52-Week High | $50.29 | $19.05 |
52-Week Low | $40.20 | $13.23 |
Enterprise Value | $93.85B | $86.65B |
Dividend Yield | 4.03% | 3.33% |
Typical Hold Time | — | 0 Days |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Exelon Corporation Common Stock
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
